Cancer Consultants (press release), TN - 36 minutes ago
... Gleevec® (imatinib) is a biological agent that binds to and slows or stops the uncontrolled growth of cancer cells with this genetic mutation. ...
| Fresh from the Pipeline: Sunitinib maleate
Nature.com (subscription), UK - 2 hours ago ... Stimulated by the success of kinase inhibitors in cancer treatment — in particular, imatinib mesylate ( Gleevec; Novartis) in the treatment of chronic myeloid ... |
|
Awarded studies of the University of Navarra Basque Research, Spain - 5 hours ago ... best oral communication was given to "Evolution in the treatment of chronic myeloid leukemia and tumors of the gastrointestinal stroma: Gleevec," by Maria ... |
|
Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee ... FDA Advisory Committee - 10 hours ago ... with chronic, accelerated, or blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy, including imatinib" (Novartis' Gleevec ... |
|
|
Researchers Seek Alternative For Leukemia Patients Resistant To ... Medical News Today (press release), UK - Apr 6, 2006 ... Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec® (imatinib), according ... |
|
A new approach to treating cancer Pittsburgh Post Gazette, PA - Apr 5, 2006 ... in oncology: Doctors now believe that the drugs Tarceva and Iressa work best in a certain subgroup of patients with lung cancer, Gleevec in particular subtypes ... |
|
Patent Application For AIDS Drug Opposed For First Time In India Medical News Today (press release), UK - Apr 4, 2006 ... Indian cancer patients and generic drug manufacturers recently opposed a Novartis patent application for Gleevec (Imatinib Mesylate), an anti-cancer drug, on ... |
|
Sutent® Approved by FDA for Treatment of Renal Cell Carcinoma and ... Cancer Consultants (press release), TN - Apr 4, 2006 ... the use of Sutent (SU 11248, sunitinib malate) for the treatment of gastrointestinal stromal tumors (GIST) that had progressed after Gleevec® (imatinib) and ... |
|
AACR: Agent Shows Value in Gleevec-Resistant CML MedPage Today, NJ - Apr 4, 2006 ... 3 - Dasatinib, a second generation tyrosine kinase inhibitor, can control chronic myelogenous leukemia (CML) in patients resistant to Gleevec (imatinib mesylate ... |
CCNMatthews (press release), Canada - Apr 4, 2006
... Dr Peter Traxler, former international project manager at Novartis Switzerland, was involved in the successful development of drugs such as Gleevec ® and now
--
Powered by NewOrleansEmail.Com http://neworleansemail.com
--~--~---------~--~----~------------~-------~--~----~
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------
You received this message because you are subscribed to the Google Groups "CMLHope" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---
